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Abstract 
Alzheimer’s disease (AD) is the most prevalent age-related neurodegenerative disease, 
pathologically characterized by the accumulation of amyloid beta (Aβ) aggregation in the brain. 
Here, we describe for the first time the development of a new, pioneering nanotechnology-based 
drug delivery approach for potential therapies of neurodegenerative diseases, particularly AD. We 
demonstrated the delivery of fluorescent carboxyl magnetic Nile Red particles (FMNPs) to the 
brains of normal mice using a functionalized magnetic field (FMF) composed of positive- and 
negative-pulsed magnetic fields generated by electromagnetic coils. The FMNPs successfully 
reached the brain in a few minutes and showed evidence of the blood-brain barrier (BBB) crossing. 
Moreover, the best FMF condition was found for inducing the FMNPs to reach the cortex and 
hippocampus regions. Under the same FMF conditions, dextran-coated Fe3O4 magnetic 
nanoparticles (MNPs) loaded with osmotin (OMNP) were transported to the brains of Aβ1-42-
treated mice. Compared to native osmotin, OMNP potently attenuate Aβ1-42-induced synaptic 
deficits, Aβ accumulation, BACE-1 expression and tau hyperphosphorylation. This magnetic drug 
delivery approach can be extended to preclinical and clinical use and may advance chance of 
success in the treatment of neurological disorders like AD in the future. 
Keywords: Alzheimer’s disease (AD), fluorescent carboxyl magnetic Nile Red particles (FMNPs), 
dextran-coated Fe3O4 magnetic nanoparticles (MNPs), osmotin, functionalized magnetic field 
(FMF). 
 
 
 
Introduction 
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is clinically characterized by 
the dysfunction of memory and cognition. The neuropathological hallmarks of AD include senile 
plaques, neurofibrillary tangles, synaptic disorder and neuronal loss.1 Several hypotheses have 
been put forward regarding AD pathology, although the Aβ cascade hypothesis is the most widely 
accepted.2,3 According to this hypothesis, Aβ peptides are prominently generated from the catalytic 
cleavage of the transmembrane glycoprotein amyloid precursor protein (APP) by β-secretase at 
the APP-N terminal and by γ-secretase at the APP-C terminus.4 Aβ1-42 is neurotoxic both in vitro 
and in vivo,5,6 the primary biochemical cascade associated with memory impairment in AD.7 
Osmotin is a 24-kDa multifunctional plant protein from tobacco (Nicotiana tabacum) and 
a member of the pathogenesis related-5 (PR-5) family of proteins that provides osmotolerance to 
plants and exhibits antifungal activity.8,9 Our group10,11 recently demonstrated the neuroprotective 
effect of osmotin against glutamate- and ethanol-induced apoptosis and neurodegeneration in 
postnatal rat brains. The neuroprotective effect of osmotin against Alzheimer’s disease has been 
reported by our group in mice.12,13 
Currently, there is no certain cure for neurological diseases such as AD, and treatment 
options are extremely limited.14 Fe3O4 MNPs, which are superparamagnetic, non-toxic and 
biocompatible, have been intensively investigated.15 Superparamagnetic iron oxide agents have 
been modified with dextran and/or other types of polymer coatings to achieve excellent 
dispersion.16-19 Dextran coating enhances the blood circulation time and stabilizes the colloidal 
solution.20,21 Magnetically guided delivery strategies have the potential to enhance the therapeutic 
profile of a broad range of pharmaceuticals by increasing their distribution to the site of action.22 
MNPs have also attracted attention due to their relatively low toxicity profile. Their 
superparamagnetic property ensures particle stability during storage and use, and their 
responsiveness to applied magnetic fields can be exploited for magnetically guided particle 
imaging.23 
Magnetic drug delivery refers to adding drugs to magnetizable particles and then applying 
magnetic fields to concentrate them at disease locations, such as solid tumors, regions of infection, 
or blood clots.24,25 The idea of using permanent magnets for drug delivery has been investigated 
for the past 30 years.26,27 This approach, however, fails to deliver micro-nano agents to deep tissues 
or provide quick control responses. Using a constant magnetic force or permanent magnets may 
cause the particles to aggregate or stick to vessel walls, which can lead to blockages. To address 
this concern, we previously suggested the use of a functionalized magnetic field (FMF), or a field 
function (FF), to replace the constant magnetic force using an electromagnetic actuator with a high 
gradient magnetic field.28,29 By intentionally changing the direction of the magnetic field, sticking 
and aggregation were prevented. We also observed that, relative to a constant magnetic field, the 
rate of magnetic nanoparticle (MNP) uptake and transport across the normal intact BBB was 
enhanced by a positive/negative pulsed magnetic field through our in vivo experiments with 
mice.30 
The primary challenges in the diagnosis (and treatment) of AD are to overcome the 
restrictive mechanism of the blood–brain barrier (BBB) and deliver adequate drugs to 
hippocampus regions located in deeper sites of the brain. Several studies have showed that the 
hippocampus plays a critical role in learning and memory.31 An FMF-guided drug-MNP conjugate 
for the treatment of AD can reach the CNS and the hippocampus regions within a few minutes, 
inducing minimal systemic effects. Moreover, the maximum amount of osmotin can reach the 
brain because it is not exposed to body fluids for an extended time. Therefore, FMF-guided OMNP 
may be more effective and potent in treating Alzheimer’s disease. It should be noted that the 
proposed FMF aims to activate the BBB crossing of the MNPs and spread them over to the broad 
brain regions for treatments of Alzheimer’s disease rather than to target the MNPs to a specific t 
region of brain like a cancer therapy. 
The purpose of this study was to study the delivery effects of osmotin-loaded magnetic 
nanoparticles to the brains of Aβ1-42-treated mice using an electromagnetic function to guide MNPs 
into brain sites, which significantly can recover brain damage due to Alzheimer’s disease. In our 
experimental setup, we assessed the differential effects of the electromagnetic guidance on the 
transport of particles across the intact BBB (Fig. 1). In our experiment, we used an in vivo 
electromagnetic guidance scheme with the significantly improved process time (9 times shorter) 
compared to KA. Min et al. 2013.32 Also, we demonstrated for the first time that, compared to 
osmotin, the electromagnetic actuator-guided OMNP reduces Aβ accumulation, BACE-1 
expression, synaptotoxicity, memory impairment and tau hyperphosphorylation in a Aβ1-42-
injected mouse model. 
 Results 
Characterization of FMNPs and OMNP  
The FMNPs nanoparticles were 0.20-0.39 µm in diameter. Morphological examination via 
transmission electron microscopy (TEM) revealed the formation of smooth spherically shaped 
nanoparticles with an average diameter of 350 nm (Fig. 2A-B). Morphological examination of the 
osmotin loaded dextran-coated Fe3O4 magnetic nanoparticles (OMNPs) via transmission electron 
microscopy (TEM) showed smooth spherically shaped nanoparticles with an average diameter of 
90 nm (Fig. 2C-D). 
In vitro cytotoxicity (MTT assay)  
The three nanoparticle cytotoxicity profiles were studied in normal HT-22 cells and human 
neuroblastoma SH-SY5Y cells using an MTT assay. Various concentrations of each test sample, 
FMNPs, MNPs, OMNP and free osmotin, were used for the studies. Four concentrations of each 
test sample were used, ranging from 50 to 200 μg/mL. From the results obtained, it was concluded 
that all of the tested samples did not possess any significant cytotoxic effects, showing 85-90% 
viability at all the studied concentrations on HT-22 cells (Fig. 2E & 2G) and SH-SY5Y cells (Fig. 
2F & 2H). Reduced cytotoxicity of the oxide nanoparticles is associated with increased particle 
solubility and modifications to the surface chemistry.33 
 
 
 
 
Electromagnetic targeted drug delivery actuator and FMF generation 
The figure 3 shows a picture and the geometric specifications of the proposed electromagnetic 
actuator. The complete explanation of each part of fig. 3 are provided in experimental section. 
 
 
Transport Results of FMNPs across the intact BBB in normal mice promoted by FMFs 
The FMNPs were injected into the mice via the tail vein and then exposed to various magnetic 
field conditions for different time intervals. The FMNP uptake was verified in the brain by confocal 
microscopy (Fig. 4 and 5). 
To assess the rate and kinetics of MNP accumulation in the brain, we first performed confocal 
imaging of the brains of mice that were subjected to an intravenous injection of fluorescent MNPs 
(0.4 mL) in the absence of FMF. We did not observe the accumulation of MNPs in the brains in 
the absence of FMF (Fig. 4g). The uptake of FMNPs into the brain was observed when the animals 
were exposed to FMF. Fig. 4a-f show the confocal micrographs of the brains of the mice that 
received an intravenous injection of fluorescent MNPs (0.4 mL) and were then exposed to various 
FMF conditions for two different time periods. The uptake and transport of the FMNPs were 
significantly higher (p<0.0001) at all of the observed experimental FMF conditions (Fig. 4a-f) 
compared to the control group (Fig. 4g). Figures 4a and 4b show the results of the application of 
the FMF using an input current of 3 A and a frequency of 0.5 Hz for 5- and 10-minute exposure 
times, respectively. In both conditions, there was uptake and transport of the FMNPs to the brain 
cortex. To select the most suitable experimental conditions for the uptake and transport of FMNPs 
to the brain, the current was increased from 3 A (2.8T/m) to 6 A (2.8T/m) while using the same 
frequency. The rate of particle transport across the BBB was increased significantly (Fig. 4c-d). 
For further confirmation, in the next experimental setup, we kept the current the same and 
increased the frequency from 0.5 Hz to 1.0 Hz (Fig. 4e-f). Compared to the conditions of 6 A and 
0.5 Hz, the transport of MNPs to the brain decreased (Fig. 4c-d), which is discussed in the 
discussion section. 
Overall, our confocal microscopy results showed that, under all of the observed FMF conditions, 
the FMNPs successfully reached the brain cortex (Fig. 4a-f), indicating that the positive and 
negative pulsing of the magnet promoted both the uptake and transport of FMNPs across the BBB. 
It should be noted that the uptake and transport across the BBB was significantly increased (p<0.01) 
using a current of 6 A and a frequency of 0.5 Hz (Fig. 4c-d). 
 
 
Uptake and transport across the BBB is significantly increased under the 6 A, 0.5 Hz FMF 
conditions and FMNPs reached the hippocampus of the mice brains 
After confirming that FMNPs crossed the BBB and reached the cortex under all six conditions of 
FMF (Fig. 4a-f), we next evaluated the hippocampus and observed that the FMNPs reached the 
hippocampus under the conditions of 6 A, 0.5 Hz FMF (Fig. 5c-d). However, at all other FMF 
conditions, we did not observe the presence of FMNPs in the hippocampus (Fig. 5a, b, e, f). Fig. 
5 B shows FMNPs present in the CA1, CA3 and DG regions of the hippocampus under the FMF 
conditions of 6-A current, 0.5-Hz frequency and a 10-minute exposure time. Thus, we suggest that 
these FMF conditions are suitable for drug delivery to the hippocampus of AD mice.  
 
FMNP administration and exposure to FMFs induced no toxicity in vivo in normal mice 
The activation of oxidative stress leading to apoptosis and genotoxicity are the key paradigm(s) of 
nanotoxicity.34-38 Although MNP deposits were detectable in the prostates of prostate cancer 
patients after a year of magnetic hyperthermia therapy, no signs of systemic toxicity were found39. 
Following intravenous administration of FMNPs and exposure to the FMFs, the toxicity was 
studied in tissue lysates of the brain. We did not observe the activation and release of caspase-3 or 
PARP-1 in the brain after FMNP injection and exposure to FMFs (Fig. 6A). The western blot 
results suggest that FMNP administration and the application of FMFs in vivo produced no 
extended immunotoxicity or cell death in the brain. 
The potential toxicity of FMNPs and FMFs was further assessed in brain sections. Nissl/cresyl 
violet staining was performed to determine the extent of neuronal viability. Histology of the cortex 
showed that, at all tested conditions, there was no neural cell death after FMNP injection and 
application of the FMFs (Fig. 6B). These results showed that FMNP administration and the 
application of FMFs produced no toxicity and neurodegeneration in the brains of mice.  
 The BBB was not disrupted by the FMNP administration and the application of FMFs in 
normal mice 
For assessing the in vivo nanotoxicity, cell viability measurements should be supplemented with 
an evaluation of organ-specific toxicity, such as breakdown of the blood–brain barrier.40,41 The 
Evans blue method for macroscopic evaluation of vascular protein leakage across the BBB has 
been widely used. Its extravasation into central and peripheral organs following a more prolonged 
time period was correlated with vascular leakage of serum albumin, and its leakage into the brain 
parenchyma indicated blood-brain barrier (BBB) disruption.42-47 The results showed that FMNP 
administration and the application of the FMFs did not alter the BBB integrity because there was 
no leakage of Evans blue into the brains of the observed mice. Moreover, after the fluorescence 
measurements, the values of the control group were the same as the values of the experimental 
groups (data not shown). Therefore, the critical conclusion of these studies is that FMNP uptake 
into the brain does not cause a major disruption of the endothelial barrier or alteration in BBB 
integrity. 
The apparent intracellular mass of the FMNPs internalized in the brain tissues was also markedly 
higher under all of the tested FMF conditions. Therefore, an FMF can be used to enhance the 
transport of FMNPs across the BBB. These results suggest that an FMF is more efficient in 
promoting FMNP transport because it reduces the aggregation phenomenon of FMNPs and, as a 
result, the FMNPs can easily penetrate the BBB. More importantly, our results clearly show the 
importance of exploring the effects of variations in the magnetic field for in vivo magnetic particle 
delivery applications. The FMF applied for 10 minutes after i.v. injection of FMNPs with a 6-
ampere current and a 0.5-Hz frequency induced enhanced uptake and crossing of the intact BBB, 
and the FMNPs subsequently reached to the mouse hippocampus.  
Therefore, we used the best condition of FMF for the osmotin delivery to the hippocampus of Aβ1-
42-induced AD mice for the treatment of AD. We injected OMNP into the Aβ1-42-induced AD mice 
via the tail vein and then exposed the mice to an FMF using a 6-A current and a 0.5-Hz frequency 
for 10 minutes. 
The OMNP treatment ameliorated Aβ1-42-induced memory impairment 
To assess whether the OMNP could overcome the Aβ1-42-induced memory impairment, we 
subjected the mice to a Morris water maze (MWM) and a Y-maze test. Using the MWM and 
observing the learning ability of the mice through the training of a hidden platform, we observed 
that the Aβ1-42-treated mice exhibited higher latencies in seconds to reach the hidden platform and 
that treatment with osmotin alone or with the OMNP (15 µg/g, body weight, i.v.) reduced the less 
latency times (p<0.05 and p<0.01, respectively) (Fig. 7A). After the training session, we removed 
the hidden platform and allowed the mice to swim freely. We observed that the Aβ1-42-treated mice 
exhibited a decreased number of platform crossings indicating Aβ1-42-induced memory impairment. 
Treatment with the OMNP reversed this Aβ1-42-induced memory impairment and significantly 
increasing (P<0.01) the platform crossing number (Fig. 7B). 
Following the MWM analysis, we evaluated the spontaneous alteration behavior percentage (%) 
of the mice and found the average total number of arm entries and successive triplets using a Y-
maze test. The spontaneous alteration behavior %, indicating spatial working memory, is a form 
of short-term memory. After a single injection of Aβ1-42, the % of the spontaneous alteration 
behavior was reduced in the Aβ1-42-treated mice compared to the control mice, suggesting Aβ1-42-
induced memory dysfunction. Treatment with the OMNP significantly increased the spontaneous 
alteration behavior % in the Aβ1-42-treated mice compared to the untreated Aβ1-42 mice (Fig. 7C), 
indicating that the OMNP more potently (P<0.01) ameliorated Aβ1-42-induced memory 
dysfunction in the Aβ1-42-treated mice (p<0.05). 
 The OMNP treatment alleviated Aβ1-42-induced synaptotoxicity 
To assess synaptic integrity after Aβ1-42 treatment, we quantified the expression of presynaptic 
vesicle membrane proteins (synaptophysin) and postsynaptic markers post-synaptic density 
protein 95 (PSD95). A western blot analysis revealed a significant reduction in synaptophysin 
levels in Aβ1-42-treated mice after 40 days post-Aβ1-42 injection compared to the control mice, 
indicating the induction of synaptic dysfunction (Fig. 7D). The OMNP treatment significantly 
increased (p < 0.01) synaptophysin expression after post-Aβ1-42 injection compared to Aβ1-42 alone 
(p<0.05) (Fig. 7D). Furthermore, the western blot results revealed a significant decrease in the 
level of PSD95 in the Aβ1-42-treated group while treatment with OMNP reduced the effect of Aβ1-
42 and significantly increased (p < 0.01) the level of PSD95 compared to Aβ1-42 treatment alone 
mice (Fig. 7D). The brain tissue was also histologically examined for PSD95 expression via 
immunofluorescence. Representative images (Fig. 7E) showed that Aβ1-42 injection reduced the 
immunofluorescence reactivity for PSD95 (FITC-labeled, green) in the CA2 and DG regions of 
the hippocampus compared to the control treatment. However, OMNP treatment significantly 
increased (p<0.01) the immunofluorescence reactivity for PSD95 compared to treatment with 
native osmotin (p<0.05) (Fig. 7E). 
The OMNP attenuated Aβ accumulation and β-site APP-cleaving enzyme-1 (BACE-1) 
expression and prevented Aβ1-42-induced hyperphosphorylation of tau 
To determine whether Aβ1-42 injection promoted Aβ accumulation, we performed a western blot 
analysis. The results showed that the levels of Aβ were significantly higher in the Aβ1-42-treated 
mice than in the control mice. The OMNP administration ameliorated this effect of Aβ1-42, as a 
significant reduction (p < 0.01) was observed in Aβ accumulation compared to treatment with bulk 
osmotin (p < 0.05) (Fig. 8A). To examine plaque formation after Aβ1-42 injection, we performed 
thioflavin S staining. In the Aβ1-42-treated mice, the number of plaques and the plaque burden (%) 
were determined, and no plaque formation was observed in the control mice. Treatment with 
OMNP significantly decreased (p < 0.01) the number of plaques and the plaque burden (%) (Fig. 
8B). 
We also analyzed the immunofluorescence of Aβ in the experimental mice. The OMNP treatment 
significantly reduced (p<0.01) the immunofluorescence reactivity of Aβ (TRITC-labeled, red) in 
the CA1 and DG regions of the hippocampus in the Aβ1-42-treated group showing enhanced 
neuroprotection (Fig. 8C). Furthermore, we examined the expression of BACE-1 after Aβ1-42 
injection, and the western blot analysis results showed that Aβ1-42 treatment significantly increased 
BACE-1 expression compared to the control treatment. The expression of active BACE-1 was 
significantly decreased (p < 0.05) due to treatment free osmotin; however, it was decreased more 
potently (p < 0.01) by the OMNP treatment (Fig. 8A). We also investigated the phosphorylation 
of the tau protein (p-tau) in the control and Aβ1-42-treated mice via western blot analysis. Treatment 
with Aβ1-42 increased the level of p-tau compared to the control treatment. The Aβ1-42-induced 
hyperphosphorylation of tau was significantly attenuated by OMNP treatment (p<0.01) compared 
to treatment with osmotin alone (p<0.05) (Fig. 8A). 
  
Discussion 
Based on the pioneering idea proposed by Freeman et al48 that fine iron particles could be 
transported through the vascular system, the use of magnetic particles for the delivery of drugs or 
antibodies to organs or tissues altered by disease has become an active and attractive field of 
research.49 The proposed method of magnetically guided drug delivery involves the following: 
first, the immobilization of a drug into MNPs; second, the injection of the drug/carrier complex 
into the subject, either via intravenous (i.v.) or intra-arterial (i.a.) injection; and, finally, the use of 
high-gradient external magnetic fields to pass the particles through BBB. To increase the 
biocompatibility of these nanostructures with cells and tissues, they are generally coated with 
hydrophilic polymers, such as starch or dextran, due to their low toxicity and high affinity for iron 
oxide (chelation and hydrogen bonding)50, whereas the therapeutic agent of interest is either 
covalently conjugated or ionically bound to the outer layer of the polymer.51 
In the first phase of this study, we demonstrated the increased sensitivity of FMNPs to an FMF 
and explored the possibility of using such fluorescent magnetic particles to access the brains of 
normal mice. An FMF may offer distinct advantages in terms of its ability to minimize cell surface 
aggregate formation and to maximize the force driving the cellular uptake and transport of particles. 
We focused on delivery across the intact BBB in normal mice. Recent studies have also 
demonstrated the use of an external magnetic field to facilitate the delivery of MNPs across the 
BBB.52,53 Our research demonstrates BBB translocation of FMNPs based on a higher resolution 
confocal analysis to pinpoint the extravasation of these particles in the brain. Furthermore, unlike 
in vitro BBB cell culture models with various limitations, our in vivo model is more suitable for 
studying the complex multi-cellular nature of the BBB and the pharmaco-distribution of the 
FMNPs. Moreover, our data indicate that magnet-mediated delivery of FMNPs can occur in the 
normal brain without disturbing the BBB integrity and that such delivery is not cytotoxic.  
The mean diameter of the FMNPs was 350 nm. An examination of the TEM micrographs revealed 
spherically shaped NPs (Fig. 2A-B). Cell viability studies showed that these magnetic particles 
were not cytotoxic at all of the tested concentrations (Fig. 2E). Under all of the FMF conditions 
tested, the transport of FMNPs across the BBB was increased (Fig. 4a-f). In contrast, when the 
magnetic field was held constant, a marked decreased fraction of particles crossed the brain or 
were actively transported across the BBB.30 When the FMF was applied, the sticking phenomenon 
among the particles inside the blood vessels decreased, which enhanced the uptake and transport 
of magnetic particles across the BBB.28,30  
Probing the role of endocytosis on the transport of MNPs is very difficult in vivo, and only a few 
such studies on the middle ear epithelium have been conducted.54,55 The Kong et al. reported a 
possible mechanism regarding how magnetic nanoparticles cross the BBB in vivo in mice due to 
the application of an external magnetic field. They showed that the 100nm magnetic nanoparticles, 
the size of which is close to our OMNPs, can internalize into brain endothelial cells by a process 
of endocytosis and maintain the barrier properties of the BBB.56 Therefore, we assumed that, in 
our in vivo study, the magnetic nanoparticles were also internalized by the endothelial cells of the 
BBB by endocytosis mechanisms, and our Evan’s blue results are consistent with the previous 
report that, after MNP injection and exposure to the FMF, the MNPs successfully crossed the BBB 
without disturbing its integrity. 
Submaximal magnetic field strengths have been previously used in vivo to avoid severe particle 
aggregations that often occur during magnetic drug delivery’s experiments.57 For the various FMF 
scenarios, we observed the best results under the condition of a 10-minute exposure time with a 6-
ampere current at a 0.5-Hz frequency, which induced enhanced uptake and crossing of the intact 
BBB and increased FMNPs that reached the hippocampus. Increased magnetic forces (or amperes) 
and increased exposure times led to more FMNPs crossing the BBB. Furthermore, we observed 
the best result when the frequency of the FMF was 0.5 Hz. Regarding the FMF, as the frequency 
was increased, less particles stuck to blood vessels, as the positive magnetic force decreased but 
the negative magnetic force was long enough to release the particles to prevent sticking. However, 
when the frequency was too high (> 0.5 Hz), the negative magnetic force was too small, and the 
particles did not have enough time to release from the blood walls. In (T. D. DO et al., 2016) 58 
experimental results of FMFs in normal mice illustrate that a 3A current provides higher BBB 
crossing of MNPs than a 1A current. Moreover, frequencies of 0.5 and 1 Hz have higher BBB 
crossing in comparison to a frequency of 0.25 Hz. Similarly, extensive simulation studies 58 with 
a realistic 3D vessel showed that a frequency of 0.5 Hz has the best conditions matching to the 
experimental results. Therefore, in this study, three conditions of 3A-0.5Hz, 6A-0.5 Hz, and 6A-1 
Hz were studied and the best condition is chosen as 6A and 0.5 Hz among them. The results from 
these in vivo experiments suggest that the best FMF can effectively enhance MNP guidance by 
preventing sticking and aggregation in blood vessels and allowing MNPs to reach the hippocampus 
within a few minutes of injection without disrupting the BBB (Fig. 5B). 
Unlike other drug delivery methods, such as that mediated by antibodies to specific cell surface 
receptors, the magnetically mediated translocation of MNPs does not appear to induce deleterious 
signal transduction events and results in minimal accumulation in other organs.59 After extensively 
studying the differential effects of FMFs on the uptake and transport of FMNPs into the brains of 
normal mice, we concluded that all of the applied FMF conditions were effective and that the 
FMNPs successfully crossed the BBB, reaching the brain within a few minutes of treatment 
without disrupting the BBB. To understand the potential for toxic effects in vivo in normal mice, 
we studied the apoptotic markers caspase-3 and PARP-1. We did not observe activation or 
elevation of the expressions of apoptotic markers caspase-3 and PARP-1 in the brain lysate of 
normal mice, which was confirmed via western blot, indicating that FMNP injection and exposure 
to an FMF are not toxic in vivo (Fig. 6A). Several reports have found that iron accumulates in 
tissues with unremarkable histological changes in vital organs, concluding the safety of the 
respective formulations.60-63 Nissl/cresyl violet staining showed that there was no 
neurodegeneration after FMNP injection or exposure to an FMF (Fig. 6B). Evans blue dye (EBD)64 
is a commonly used tracer for the estimation of plasma volume in humans and the study of vascular 
permeability in animal models. Our results demonstrated that FMNP administration and exposure 
to an FMF did not change the BBB integrity in normal mice and did not induce a major disruption 
of the endothelial barrier because there was no leakage of Evans blue observed in the brains of 
mice. Since the blood-brain barrier was leakier in a group of people with Alzheimer's disease than 
their healthy counterparts, 65,66 OMNPs can reach to the brain of AD mice without further breaking 
anymore the BBB integrity.  
The present study is the first report to provide evidence that osmotin-conjugated magnetic 
nanoparticles attenuates the Aβ1-42-induced memory dysfunction, synaptic disorder and tau 
hyperphosphorylation in mice hippocampus and to report the best condition of FMFs for the drug 
delivery. The osmotin covalently binds to nanoparticles through the interaction between amine 
group on osmotin and carboxyl group on magnetic particles. Molecules that contain amine groups 
such as protein (osmotin) or peptide, can be conjugated to the surface functional group -COOH of 
magnetic beads easily. The MNPs with dextran coating stabilize the nanoparticles, achieve 
excellent dispersion and stabilizes the colloidal solution.67,68 Furthermore, we did not observe any 
type of precipitation of OMNP which is the most significant feature when the protein-conjugated 
particles are going bad. C. Wang et al, 2013 reported that the release of doxorubicin (DOX) from 
magnetic nanoparticles is pH dependent.69 They investigated the drug-releasing behaviors of 
Fe3O4@PPy-PEG-DOX under different pH values like in pH 5.0, 6.0, and 7.4 phosphate buffers. 
Within 24 h, about 48% of DOX was released from the nanocomposite at pH 5.0, compared with 
13% and 4% of DOX release at pH 6.0 and 7.4, respectively. 69 The covalent bonds in the 
nanoparticles-drug conjugates can hold the drug firmly in the circulation at physiological pH 
conditions, and there will be less drug released into healthy tissue and can only be released when 
there is an acidic environment. 70 Moreover, another study also revealed that the pH in the brains 
of AD patients is lower than that in the brains of healthy individuals. 71 So, on the basis of previous 
research work, the one possible mechanism/explanation for osmotin release is that the therapeutic 
agent (osmotin) will show controlled release at the target site (AD brain) in acidic pH condition 
and will not be released at physiological pH70 of the body.  
The Aβ1-42 (3 µL/5 min/mouse) triggered memory dysfunction, an important indicator of synaptic 
disorder (a key feature of early phase AD), and hyperphosphorylated tau. The 
intracerebroventricular Aβ injection model is a useful complement to transgenic mouse models72 
for the development and evaluation of therapeutic approaches to AD pathology because the 
mechanisms underlying many characteristics of AD, including the induction of tau 
phosphorylation, synaptotoxicity, apoptosis and neurodegeneration, remain elusive. 
Our experiment (Aβ1-42-injection model) revealed a significant reduction in memory function 
observed through the MWM and Y-Maze test. We observed that, compared to treatment with 
osmotin alone, OMNP treatment improved memory, assessed by a reduction in the escape latency 
and the number of platform crossings during the probe test. In the Y-maze, we observed reduced 
spontaneous alteration behavior related to the hippocampus.73 We observed that the OMNP 
treatment ameliorated the effects of Aβ1-42 on the spontaneous alteration behavior, thus reducing 
the degree of spatial memory impairment. The observed improvements in memory function for the 
OMNP treatment, demonstrating the neuroprotective effect of OMNP against Aβ1-42-induced 
memory impairment. 
Landmarks studies have reported Aβ-induced synaptic loss and disorders in animal models of 
AD.74 The expression of the presynaptic marker, synaptophysin, was decreased in the brains of 
patients with AD and in an Aβ animal model of AD.75,76 Our results showed that Aβ1-42-treated 
mice significantly reduced synaptophysin levels in the hippocampus. Moreover, a decreased level 
of the postsynaptic protein marker, PSD95, is also implicated in the Aβ model of AD.74 The 
synaptophysin and PSD95 levels in the Aβ1-42-treated mice were protected by OMNP 
administration, thereby suggesting that protecting pre-and post-synaptic protein markers improves 
spatial memory. 
In AD, Aβ production and aggregation in the human brain has been associated with neuronal 
dysfunction and memory disorders.77 BACE-1 is the primary initiating enzyme, and its activity is 
the rate-limiting step involved in APP processing and Aβ production.78 The elevated expression 
of activated BACE-1 has been examined in the brain during late-onset sporadic AD, which is 
associated with neuronal loss and spatial memory impairment in 5XFAD APP/PS1 mice.79,80 
Interestingly, recent studies have shown that BACE-1 expression is up-regulated by Aβ1-42.81 The 
results of the present study consistently showed increased levels of BACE-1 expression in the Aβ1-
42-treated mice. The total Aβ level and Aβ1-42-induced BACE-1 expression after Aβ1-42 injection 
were attenuated by OMNP treatment (Fig. 8A-C). Recently, studies have reported that soluble Aβ 
oligomers, generated from synthetic Aβ peptides and extracted from the brain of patients with AD, 
promote hyperphosphorylation of the tau protein.82 Hyperphosphorylated tau induced memory 
impairment and loss of functional synapses in a transgenic mouse model.83 Our results showed 
that OMNP alleviates the hyperphosphorylation of the tau protein (Fig. 8A). 
Conclusion 
This study for the first time showed its effectiveness for treating of Alzheimer’s disease using 
OMNP and an electromagnetic drug delivery method for guiding FMNPs to the deep brain region 
of mice. Our study demonstrates the ability to regulate the CNS distribution of FMNPs using an 
external electromagnetic field (i.e., functionalized magnetic field), and demonstrate the ability of 
FMNPs to cross the BBB and to accumulate in the hippocampus of mice brains, which can be 
beneficial for treatments of various CNS diseases. Our results also demonstrate that the OMNP 
attenuated Aβ1-42-induced memory impairment, synaptotoxicity and tau hyperphosphorylation. 
Based on these results, the combination of osmotin and a magnetic nanoparticles-based delivery 
system with external functional magnetic guidance may open new avenues for therapeutic 
approaches for the treatment of various chronic and metabolic diseases, including 
neurodegenerative diseases, such as AD. 
 
Experimental Section  
Most parts of this section are provided in the Supplementary Information.84-87 
Properties of Fluorescent Carboxyl Magnetic Nile Red Particles (FMNPs), 
The fluorescent carboxyl magnetic Nile Red particles (FMNPs), 1% w/v, polymerized with styrene, 
were purchased from Spherotech (Catalog No: FCM-02556-2). The nanoparticle size was 0.20-
0.39 µm in diameter and its average size was 0.35 µm. Based on conductometric titration, the 
parking area was 75 Angstroms squared with 5.13x10^5 carboxyl groups/bead. The FMNPs 
excitation and emission spectra ranged from 450–550 nm and 500-600 nm respectively, and it 
showed highly efficient fluorescence in the Fluorescein isothiocyanate channel. The FMNPs 
Images were captured with a confocal laser scanning microscope (FluoView FV 1000;Olympus, 
Tokyo, Japan), with argon ion laser. 
Preparation of Osmotin-Loaded Magnetic Nanoparticles (OMNP)  
The dextran-coated Fe3O4 magnetic nanoparticles (MNPs) were purchased from MagQu Co., Ltd. 
Taiwan. Osmotin was conjugated with dextran-coated magnetic nanoparticles using a NanoQ-
Carboxyl Labeling Kit (Cat. No. KT-COO-0060-ISE). 
Electromagnetic drug delivery actuator and functionalized magnetic field generation 
The proposed electromagnetic actuator consisted of a two-coil core system. The coils were made 
of 1-mm diameter copper wire with 7000 turns and diameter d = 1.0 mm. For each coil, a core was 
added to increase the magnetic field density. The coils were made of a soft magnet cobalt-iron 
alloy, type VACOFLUX 50. The coils and cores were used to produce a magnetic field and to 
concentrate the field in the working area, respectively. The proposed actuation system can generate 
adequate magnetophoretic forces for nanoparticle steering in a vascular model.29 Figure 3 shows a 
picture and the geometric specifications of the proposed electromagnetic actuator. Figure 3A 
illustrates the experimental setup of the electromagnetic actuator system. The magnetic field at the 
ROI had a 60-mm diameter at the center of the actuation system and was designed for tests on 
mice. The magnetic force was controlled using DC power supplies and regulating the current in 
the coil. Currents up to 17 A could be applied to the coil-core system, which corresponded to a 
resistance of 20 Ω and an inductance of 0.42 H. The rated power of the DC power supply was 6 
kW.  
The functionalized magnetic field was introduced to avoid the sticking phenomenon and to 
increase the rate of MNP uptake.28,29 In this scheme, we sequentially turned on and off each coil 
to produce a positive- and negative-pulsed magnetic field. In the proposed approach, the 
functionalized magnetic field scheme is the combination of two pulsed magnetic fields in reverse 
directions. Through our simulations, FMF is proven to be effective and prevent sticking and 
aggregation.  Figure. 3B shows the current flow in the coils, the magnetic force generated in each 
coil, and the total functionalized magnetic force. The on duration of the left coil compared to the 
right coil was set to 3:1, which were chosen based on our extensive simulation studies and in vitro 
experimental studies with a Y-channel.28,29 
The control system of the electromagnetic actuation is illustrated in Figure 3C. The control 
system activates the actuators based on the designed FMF to promote BBB crossing. The gradient 
of the magnetic field (left coil 6 Ampere) has been simulated in Figure 3D. It has high intensity in 
the region of interest (the mouse brain). The proposed FMF excites particle movement in the 
vascular system and allows the particles to reach broader tissue sites in the mouse brain by 
overcoming sticking and aggregation. 
Fluorescent magnetic particle (FMNPs) treatment in normal mice 
The mice were randomly divided into the following seven groups. All mice were treated 
intravenously with 0.4 mL fluorophore-labeled FMNPs and then exposed to various conditions of 
FMFs for different time intervals. Using Nile Red fluorescent carboxyl magnetic particles 
(FMNPs), we demonstrated the ability of FMNPs to access the mouse brain in vivo by crossing 
the normal intact BBB under six different FMF conditions, and the details are provided in Table 
1. 
Table 1. Table shows the details of the in vivo experiment (Figures 4 and 5), including the mouse 
groups, the FMF conditions, the exposure time to the FMF after i.v. injection of the FMNPs, the 
dose of the FMNPs and the size of the FMNPs. 
Mice 
groups 
FMF 
Exposure time 
to FMF 
FMNPs (dose) 
FMNPs 
(size) 
a) 
3A 
(0.5 Hz) 
5 minutes 400 µL 200-390 nm 
b) 
3A 
0.5 Hz) 
10 minutes 400 µL 200-390 nm 
c) 
6A 
(0.5 Hz) 
5 minutes 400 µL 200-390 nm 
d) 
6A 
(0.5 Hz) 
10 minutes 400 µL 200-390 nm 
e) 
6A 
(1.0 Hz) 
5 minutes 400 µL 200-390 nm 
f) 
6A 
(1.0 Hz) 
10 minutes 400 µL 200-390 nm 
g) NIL NIL 400 µL 200-390 nm 
 
Mice were sacrificed after treatment. All efforts were made to minimize the number of mice 
used and their suffering. The experimental procedures were approved by the animal ethics 
committee of the Division of Applied Life Sciences, Department of Biology at Gyeongsang 
National University, South Korea.  
Drug treatment 
Human Aβ1-42 peptide was prepared as a stock solution at a concentration of 1 mg/ml in sterile 
saline solution, followed by aggregation via incubation at 37 °C for 4 days. The aggregated Aβ1-42 
peptide or vehicle (0.9% NaCl, 3 μL/5 min/mouse) was stereotaxically administered 
intracerebroventricularly using a Hamilton microsyringe (− 0.2 mm anteroposterior (AP), 1 mm 
mediolateral (ML) and − 2.4 mm dorsoventral (DV) to the bregma) under anesthesia in 
combination with 0.05 ml/100 g body weight Rompun (xylazine) and 0.1 ml/100 g body weight 
Zoletil (ketamine). We performed the stereotaxic surgical procedure in a separate heated room in 
which the heating system was designed to control the body temperature (maintained at 36 °C–
37 °C). The osmotin-treated group received a single dose of 15 μg/g osmotin (dissolved in 0.9% 
NaCl saline) administered intravenously (i.v.). The OMNP-treated group received a single dose of 
15 μg/g of OMNP (dissolved in 0.9% NaCl saline) administered intravenously (i.v.). The control 
mice received an equal volume of 0.9% NaCl saline i.v. at 40 days post-injection with 0.9% NaCl.  
Data analysis 
The western blot bands were scanned and analyzed via densitometry using a Sigma Gel System 
(SPSS Inc., Chicago, IL). The density values were expressed as the means ± standard error mean 
(SEM). Image-J software was used for the immunohistological quantitative analysis. A one-way 
analysis of variance (ANOVA) followed by a two-tailed independent Student’s t-test was used to 
compare the treated groups and the control. The calculations and graphs were made using Prism 5 
software (Graph-Pad Software, In., San Diego, CA). For the FMNP treatment in normal mice, a 
p-value <0.01 was considered statistically significant. The symbol *** represents a significant 
difference compared to the control group (***p<0.0001). The symbol ** represents a significant 
difference within the experimental groups that received the functionalized magnetic field 
(**p<0.01). For the osmotin and OMNP treatment compared to the Aβ1-42-treated group, P values 
less than 0.05 were considered statistically significant.  
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Figure legends 
Fig. 1 Schematic representation of the differential effects of the functionalized magnetic field on 
the transport of magnetic particles across the intact blood brain barrier in normal mice. In our 
experimental setup, the functionalized magnetic field was generated using an electromagnetic 
actuator, and the time for each experiment was 10 minutes, which is 9 times shorter than in the 
previously reported uptake and transport studies. Our results showed that, under all of the observed 
functionalized magnetic field conditions, the magnetic particles successfully crossed the BBB and 
reached the brain. Importantly, we did not observe any histological changes or neurotoxicity in the 
brain after the experiments. Moreover, the blood brain barrier integrity was also not disrupted by 
magnetic particle administration and the functionalized magnetic field. 
Fig. 2 Morphological observations and in vitro cytotoxicity of the magnetic particles (A) a TEM 
micrograph of the FMNPs (scale bar = 200 nm); (B) a magnified TEM micrograph of the FMNPs 
(scale bar = 50 nm); (C) a TEM micrograph of the dextran-coated MNPs (scale bar = 200 nm); 
and (D) a TEM micrograph of the dextran-coated MNPs (scale bar = 100 nm). All three 
nanoparticles cytotoxicity profiles were studied in normal HT-22 cells and normal SH-SY5Y cells 
using an MTT assay. (E) The MTT assay of the FMNPs in HT-22 cells; (F) The MTT assay of the 
FMNPs in SH-SY5Y cells; (G) The MTT assay of the Osmotin, MNPs and the OMNP in HT-22 
cells; (H) The MTT assay of the Osmotin, MNPs and the OMNP in SH-SY5Y cell lines. Four 
concentrations, ranging from 50 to 200 μg/mL, of each of the test sample, FMNPs, MNPs, OMNP 
and free osmotin, were used. We observed that the nanoparticles were biocompatible in both types 
of cells. 
Fig. 3 (A) Experimental setup of the electromagnetic drug delivery system for guidance of the 
nanocontainer-drug conjugates in vivo (B) The input current to each coil to generate the positive 
and negative pulsed magnetic field (C) A schematic of the proposed drug delivery system 
consisting of the magnetic field function, the actuation system, and the control system setup (D) 
The system in practice has been simulated (left coil 6 A) to show the distribution and direction of 
the magnetic force. 
Fig. 4 A functionalized magnetic force enhances BBB crossing and transport of FMNPs in the 
brain. The confocal analysis demonstrated accumulation of the FMNPs in the cortex facilitated by 
the application of an FMF. Representative images of brain sections from the mice. 
(a) FMNP + FMF of 3 A, 0.5 Hz for 05 minutes. 
(b) FMNP + FMF of 3 A, 0.5 Hz for 10 minutes. 
(c) FMNP + FMF of 6 A, 0.5 Hz for 05 minutes. 
(d) FMNP + FMF of 6 A, 0.5 Hz for 10 minutes. 
(e) FMNP + FMF of 6 A, 1.0 Hz for 05 minutes. 
(f) FMNP + FMF of 6 A, 1.0 Hz for 10 minutes. 
(g) Control group, i.v. injection of FMNPs but with no exposure to an FMF. 
Scale bar=50 µm (a-g) 
Histogram showing the results analyzed using Image J. The data are expressed as the mean ± SEM 
of the experiments performed in triplicate (n=3). Significant differences were evaluated using a 
one-way analysis of variance (ANOVA) followed by a Student’s t-test. Differences were 
considered statistically significant. Symbol *** represents a significant difference compared to the 
control group (***p<0.0001). Symbol ** represents a significant difference within the 
experimental groups supplied with the functionalized magnetic field (**p<0.01). 
Fig. 5 (A) FMNPs reached the hippocampus under a 6-A, 0.5-Hz FMF (Figure 5A, c-d). However, 
at all the other FMF conditions, we did not observe the presence of FMNPs in the hippocampus 
(Figure 5A, a, b, e, f). Figure 5 B shows that the FMNPs are present in the CA1, CA3 and DG 
regions of the hippocampus after exposure for 10 minutes to the 6-A, 0.5-Hz FMF. 
Fig. 6 FMNP administration and exposure to a FMF induced no toxicity in vivo. (A) 
Representative western blots of caspase-3 and PARP-1 are sown. β-actin was used as a loading 
control. (B) Nissl staining was performed to observe the extent of neuronal cell death. 
Representative photomicrographs of cresyl violet-stained brain slices after FMNP administration 
and exposure to a FMF are shown. 
Fig. 7 The OMNP ameliorated memory impairment in the Aβ1-42-treated mice. The number of 
mice (n = 13) per group was used for the behavioral analysis. (A) The mean escape latency (sec) 
to the hidden platform during training session. (B) The number of platform crossings over the 
previous platform place during the probe test. (C) The percentage of spontaneous alteration 
behavior. (D) Immunoblot analysis of synaptophysin and PSD95 in the hippocampus of the mice. 
The bands were quantified using Sigma Gel software, and the differences are represented by a 
histogram. β-actin was used as a loading control. The density values are expressed in arbitrary 
units (A.U) as the means ± S.E.M. for the respective indicated protein (n = 8 mice/group). (E) The 
immunofluorescence of PSD95 was used as the immunoreactivity of the hippocampus of 
experimental mice (n = 5 mice/group). Magnification 10x. Scale bar = 50 µm. P values less than 
0.05 were considered statistically significant. 
Fig. 8 The OMNP alleviated Aβ accumulation, β-site APP cleaving enzyme 1 (BACE-1) 
overexpression and Aβ-induced tau hyperphosphorylation. (A) Immunoblot analysis of Aβ, 
BACE-1 and p-tau in the hippocampus of the mice. The bands were quantified using Sigma Gel 
software, and the differences are represented by a histogram. β-actin was used as a loading control. 
The density values are expressed in arbitrary units (A.U) as the means ± S.E.M. for the respective 
indicated protein (n = 8 mice/group). (B) Thioflavin S staining demonstrating the formation of Aβ 
plaques at 40 days post-Aβ1-42 injection. Treatment with the OMNP significantly reduced the 
number and burden of plaques (%) compared with Aβ1-42 treatment alone (n = 5 mice/group). 
Magnification 10x. Scale bar = 100 μm. (C) Immunofluorescence of Aβ was used as the 
immunoreactivity of the hippocampus of experimental mice (n = 5 mice/group). Magnification 
10x. Scale bar = 50 µm. P values less than 0.05 were considered statistically significant. 
 
